Nalaganje...

Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth

Targeted cancer therapies, which act on specific cancer-associated molecular targets, are predominantly inhibitors of oncogenic kinases. While these drugs have achieved some clinical success, the inactivation of kinase signaling via stimulation of endogenous phosphatases has received minimal attenti...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Invest
Main Authors: Sangodkar, Jaya, Perl, Abbey, Tohme, Rita, Kiselar, Janna, Kastrinsky, David B., Zaware, Nilesh, Izadmehr, Sudeh, Mazhar, Sahar, Wiredja, Danica D., O’Connor, Caitlin M., Hoon, Divya, Dhawan, Neil S., Schlatzer, Daniela, Yao, Shen, Leonard, Daniel, Borczuk, Alain C., Gokulrangan, Giridharan, Wang, Lifu, Svenson, Elena, Farrington, Caroline C., Yuan, Eric, Avelar, Rita A., Stachnik, Agnes, Smith, Blake, Gidwani, Vickram, Giannini, Heather M., McQuaid, Daniel, McClinch, Kimberly, Wang, Zhizhi, Levine, Alice C., Sears, Rosalie C., Chen, Edward Y., Duan, Qiaonan, Datt, Manish, Haider, Shozeb, Ma’ayan, Avi, DiFeo, Analisa, Sharma, Neelesh, Galsky, Matthew D., Brautigan, David L., Ioannou, Yiannis A., Xu, Wenqing, Chance, Mark R., Ohlmeyer, Michael, Narla, Goutham
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2017
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5451217/
https://ncbi.nlm.nih.gov/pubmed/28504649
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI89548
Oznake: Označite
Brez oznak, prvi označite!